Clinical Trial Update: UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating UB-421 with an optimized background regimen in patients with multi-drug resistant HIV-1 infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• UB-421 (anti-CD4 antibody)

Snippet

Sponsor: United BioPharma | Conditions: HIV-1 Infection | Phase 2 | Status: UNKNOWN